The GeneStrat® Liquid Biopsy Test Earns Approval from NY State-CLEP
The GeneStrat test, a liquid biopsy test used in lung cancer, has earned approval from NY State-CLEP, along with several other demanding certifications.
×
254 Results
The GeneStrat test, a liquid biopsy test used in lung cancer, has earned approval from NY State-CLEP, along with several other demanding certifications.
The Positive Bioscience agreement will make GeneStrat and VeriStrat tests available in India
Biodesix is making an oral presentation at SITC regarding a testing methodology that may identify primary immunotherapy resistance in patients
Biodesix leaders shared commercial and pipeline updates at the annual qPCR and dPCR Congress
VeriStrat test saved an average of $1,050 per patient while improving survival outcomes (as compared to patients treated without the use of the test).
Peer reviewed journal: VeriStrat test identifies patients with squamous cell lung cancer who are more likely to have improved survival on afatanib (Gilotrif)
Biodesix announces new data, presented at AMP2017, supporting the analytic validity of automated RNA extraction with the GeneStrat test
Findings in the AACR Journal on melanoma patient outcomes after anti PD1 therapy; a serum protein signature predicted survival.
A new study demonstrates that VeriStrat can help physicians improve quality care and cancer care planning for patients with advanced lung cancer.
A new study published in Current Medical Research and Opinion shows that VeriStrat changes treatment decisions for patients with lung cancer.
A recent study published in the peer-reviewed journal Managed Care affirms VeriStrat; demonstrates the value of the VeriStrat lung cancer test
Interim study results: Veristrat testing impacts lung cancer treatment in all stages; early stage patients get significantly different treatments after test
Biodesix and Bioyong announced a $38M deal for development and commercialization of VeriStrat in China.
Biodesix commended the Centers for Medicare & Medicaid Services (CMS) for publishing preliminary 2018 rates for clinical diagnostic laboratory tests.
Biodesix is presenting two talks on DNA process optimization at the Cancer Genomics Consortium
Clin-TOF successfully integrated into VeriStrat® workflow
Biodesix released data at ASCO-SITC on a new assay that measures PD-L1 in the blood of cancer patients.
Dr. Jeffrey Weber will present study results of new Biodesix immunotherapy test at ITOC4
Biodesix's GeneStrat liquid biopsy test now includes ROS1 and RET mutations. The test helps physicians make treatment decisions for cancer patients.
Blood-based diagnostic approach to PD-L1 testing that shows concordance with immunohistochemistry; new data presented at EORTC
Biodesix and Progenetics have entered into an international agreement; Biodesix tests will be available in Israel for the first time.
New Biodesix data on liquid biopsy genomic tests, evaluation of biological processes underlying mass spectrometry proteomic assays of human serum
Biodesix will present data on blood-based diagnostic testing for PD-L1 at ASCO-SITC 2017; ddPCR test measuring mRNA expression from immune and cancer cells
Biodesix will present posters and an oral presentation of data at SITC 2017 Annual Meeting.
Biodesix will present data from three studies at AACR 2017 annual meeting, on genomic and proteomic assays.